AU2017279352B2 - Lysine conjugated immunoglobulins - Google Patents

Lysine conjugated immunoglobulins Download PDF

Info

Publication number
AU2017279352B2
AU2017279352B2 AU2017279352A AU2017279352A AU2017279352B2 AU 2017279352 B2 AU2017279352 B2 AU 2017279352B2 AU 2017279352 A AU2017279352 A AU 2017279352A AU 2017279352 A AU2017279352 A AU 2017279352A AU 2017279352 B2 AU2017279352 B2 AU 2017279352B2
Authority
AU
Australia
Prior art keywords
immunoglobulin
amino acid
antigen
residue
binding portion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017279352A
Other languages
English (en)
Other versions
AU2017279352A1 (en
Inventor
Earl Albone
Jared Spidel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59315675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2017279352(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2017279352A1 publication Critical patent/AU2017279352A1/en
Application granted granted Critical
Publication of AU2017279352B2 publication Critical patent/AU2017279352B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/02—Aminoacyltransferases (2.3.2)
    • C12Y203/02013—Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017279352A 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins Active AU2017279352B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662348410P 2016-06-10 2016-06-10
US62/348,410 2016-06-10
PCT/JP2017/021672 WO2017213267A1 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Publications (2)

Publication Number Publication Date
AU2017279352A1 AU2017279352A1 (en) 2018-12-13
AU2017279352B2 true AU2017279352B2 (en) 2024-07-25

Family

ID=59315675

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017279352A Active AU2017279352B2 (en) 2016-06-10 2017-06-12 Lysine conjugated immunoglobulins

Country Status (21)

Country Link
US (2) US10941431B2 (OSRAM)
EP (1) EP3468614A1 (OSRAM)
JP (1) JP7041077B2 (OSRAM)
KR (1) KR102538866B1 (OSRAM)
CN (1) CN109475642B (OSRAM)
AU (1) AU2017279352B2 (OSRAM)
BR (1) BR112018075253A2 (OSRAM)
CA (1) CA3026991A1 (OSRAM)
CL (1) CL2021003383A1 (OSRAM)
CO (1) CO2018013314A2 (OSRAM)
IL (1) IL263329B (OSRAM)
JO (1) JOP20180118A1 (OSRAM)
MX (1) MX419566B (OSRAM)
MY (1) MY202858A (OSRAM)
NZ (1) NZ748605A (OSRAM)
PE (1) PE20190340A1 (OSRAM)
PH (1) PH12018502594A1 (OSRAM)
RU (2) RU2021136863A (OSRAM)
SG (1) SG11201810470XA (OSRAM)
UA (1) UA126799C2 (OSRAM)
WO (1) WO2017213267A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018007451A (es) 2015-12-18 2018-11-09 Eisai R&D Man Co Ltd Inmunoglobulinas conjugadas con lisina c-terminal.
CA3026991A1 (en) 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins
MA55884A (fr) * 2019-05-09 2022-03-16 Merus Nv Domaines variants pour la multimérisation de protéines et leur séparation
GB201907093D0 (en) * 2019-05-20 2019-07-03 Ucl Business Plc Antibody functionalisation
CN115335406B (zh) * 2020-02-12 2026-01-30 伊莱利利公司 抗体或抗原-结合片段的结晶
US20230242671A1 (en) * 2020-03-25 2023-08-03 Eli Lilly And Company Multispecific binding proteins and methods of developing the same
JP7787101B2 (ja) * 2020-05-20 2025-12-16 ヤンセン バイオテツク，インコーポレーテツド グリコシル化Ｆｃドメインを含むタンパク質の部位特異的コンジュゲーションのための方法
CA3193819A1 (en) * 2020-09-25 2022-03-31 Anne De Groot Retro-inverso regulatory t cell epitopes
KR20240049342A (ko) * 2021-08-27 2024-04-16 얀센 바이오테크 인코포레이티드 항-psma 항체 및 이의 용도
CN115947830B (zh) * 2022-12-27 2023-09-12 优洛生物(上海)有限公司 一种经改造的抗体、其制备方法及其用途
WO2024182569A2 (en) 2023-02-28 2024-09-06 Eisai R&D Management Co., Ltd. Anti-psma antibodies, conjugates, and methods of use
WO2024211135A2 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
CN119375471A (zh) * 2023-07-26 2025-01-28 菲鹏生物股份有限公司 抗体和抗体缀合物及其用途
WO2025199464A1 (en) 2024-03-22 2025-09-25 Eisai R&D Management Co., Ltd. Anti-trop2 antibody-drug conjugates and methods of use
CN120779021A (zh) * 2024-04-08 2025-10-14 菲鹏生物股份有限公司 抗体缀合物及其用途
WO2026044149A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Synthesis of drug-linker combinations for antibody-drug conjugates
WO2026044039A2 (en) 2024-08-21 2026-02-26 Eisai R&D Management Co., Ltd. Anti-cd73 antibodies, conjugates, and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106643A1 (en) * 2015-12-18 2017-06-22 Morphotek, Inc. C-terminal lysine conjugated immunoglobulins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
ES2642214T3 (es) * 2004-01-21 2017-11-15 Novo Nordisk Health Care Ag Conjugación de péptidos mediante transglutaminasa
CA2930801C (en) * 2010-11-05 2019-05-28 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013176516A1 (ko) 2012-05-24 2013-11-28 한화케미칼 주식회사 트랜스글루타미나아제를 이용하여 제조한 항체-약물 결합체 및 이의 용도
EP2916872B1 (en) * 2012-11-09 2019-02-27 Innate Pharma Recognition tags for tgase-mediated conjugation
US8921526B2 (en) 2013-03-14 2014-12-30 Abbvie, Inc. Mutated anti-TNFα antibodies and methods of their use
JP6744212B2 (ja) * 2013-06-21 2020-08-19 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． ポリペプチドの酵素的結合
BR112016000585A2 (pt) * 2013-07-11 2018-03-20 Novartis Ag modificações quimioenzimáticas sítio-específicas de proteína
EP3027224B1 (en) * 2013-07-31 2020-06-03 Rinat Neuroscience Corp. Engineered polypeptide conjugates using transglutaminase
CN106456798B (zh) 2014-04-25 2021-02-12 瑞纳神经科学公司 具有高药物负载的抗体-药物缀合物
CA3026991A1 (en) 2016-06-10 2017-12-14 Eisai R&D Management Co., Ltd. Lysine conjugated immunoglobulins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106643A1 (en) * 2015-12-18 2017-06-22 Morphotek, Inc. C-terminal lysine conjugated immunoglobulins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dennler, P. et al., 'Transglutaminase-Based Chem-Enzymatic Conjugation Approach Yields Homogenous Antibody-Drug Conjugates', Bioconjugate Chem., (2014-02-03), vol. 25, pages 569-578, doi: 10.1021/bc400574z. *
Deonarain, M. et al., 'Emergin formats for next-generation antibody drug conjugates', Expert Opinion of Drug Discovery, (2015), vol. 10, no. 5, pages 463-481, doi:10.1517/17460441.2015.1025049. *
Josten, A. et al., 'Use of microbial transglutaminase for the enzymatic biotinylation of antibodies', Journal of Immunological Methods, (2000), vol. 240, pages 47-54. *
Mindt, T. et al., 'Modification of Different IgG1 Antibodies via Glutamine and Lysine using Bacteria and human Tissue Transglutaminase', Bioconjugate Chem., (2008), vol. 19, pages 271-278, doi: 10.1021/bc700306n. *

Also Published As

Publication number Publication date
CA3026991A1 (en) 2017-12-14
US20180044711A1 (en) 2018-02-15
RU2021136863A (ru) 2022-02-01
SG11201810470XA (en) 2018-12-28
WO2017213267A1 (en) 2017-12-14
RU2018145507A (ru) 2020-07-10
KR102538866B1 (ko) 2023-06-02
NZ748605A (en) 2023-05-26
CO2018013314A2 (es) 2019-02-19
US11753669B2 (en) 2023-09-12
UA126799C2 (uk) 2023-02-08
RU2018145507A3 (OSRAM) 2020-10-15
MY202858A (en) 2024-05-25
KR20190018159A (ko) 2019-02-21
US20210171998A1 (en) 2021-06-10
MX2018015331A (es) 2019-08-16
PH12018502594A1 (en) 2019-10-14
BR112018075253A2 (pt) 2019-04-30
CL2021003383A1 (es) 2022-08-19
MX419566B (es) 2025-01-14
JP7041077B2 (ja) 2022-03-23
JOP20180118A1 (ar) 2019-01-30
IL263329B (en) 2022-05-01
EP3468614A1 (en) 2019-04-17
US10941431B2 (en) 2021-03-09
RU2762939C2 (ru) 2021-12-24
PE20190340A1 (es) 2019-03-07
IL263329A (en) 2018-12-31
JP2019525897A (ja) 2019-09-12
CN109475642A (zh) 2019-03-15
AU2017279352A1 (en) 2018-12-13
CN109475642B (zh) 2023-05-02

Similar Documents

Publication Publication Date Title
US11753669B2 (en) Lysine conjugated immunoglobulins
US12214050B2 (en) C-terminal lysine conjugated immunoglobulins
EP3310816B1 (en) Cys80 conjugated immunoglobulins
EP3240573A1 (en) Enzymatic conjugation of polypeptides
CA3008645C (en) C-terminal lysine conjugated immunoglobulins
WO2025093562A1 (en) Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
HK40046837A (en) Cys80 conjugated immunoglobulins
CN118922447A (zh) 靶向叶酸受体α的抗体-药物缀合物及使用方法
CN120882866A (zh) Alpp特异性变体抗原结合分子
HK1252625B (en) Cys80 conjugated immunoglobulins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)